Drug evaluation: Dabigatran etexilate, a thrombin inhibitor for the prevention of venous thromboembolism and stroke

Current Opinion in Investigational Drugs

Volumn 8, Issue 9, 2007, Pages 758-768

  Ieko, M ^a  

^a HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; AZD 0837; DABIGATRAN; DABIGATRAN ETEXILATE; DABIGATRAN ETEXILATE METHANESULFONATE; DIPYRIDAMOLE; ENOXAPARIN; HEPARIN; HIRUDIN; MELAGATRAN; PANTOPRAZOLE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TGN 167; UNCLASSIFIED DRUG; WARFARIN; XIMELAGATRAN; BENZIMIDAZOLE DERIVATIVE; FIBRINOLYTIC AGENT; PRODRUG; PYRIDINE DERIVATIVE; THROMBIN;

BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; DEEP VEIN THROMBOSIS; DIZZINESS; DOG; DOSE TIME EFFECT RELATION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; EXPERIMENTAL RAT; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; GUINEA PIG; HEART ATRIUM FIBRILLATION; HEMATOMA; HUMAN; INJECTION SITE BLEEDING; LIVER INJURY; NONHUMAN; PAIN; PARTIAL THROMBOPLASTIN TIME; POLYURIA; PROTHROMBIN TIME; RABBIT; REACTION ANALYSIS; REVIEW; RHESUS MONKEY; STROKE; STRUCTURE ACTIVITY RELATION; SURFACE PLASMON RESONANCE; SWINE; THROMBOCYTE POOR PLASMA; VENOUS THROMBOEMBOLISM; WEAKNESS; ANIMAL; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PATENT; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANIMALS; BENZIMIDAZOLES; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR STRUCTURE; PATENTS; PRODRUGS; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOEMBOLISM; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 34548335207     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. 166797 Licensing information. Daiichi Pharmaceutical Co Ltd COMPANY COMMUNICATION 1994 October 18
2. 275466 Astra R&D presentation, London, UK. Muhsin M IDDB MEETING REPORT 1998 January 23
3. 290810 Refludan (lepirudin (rDNA) for injection), first available treatment for heparin-induced thrombocytopenia, released for US market. Hoechst Marion Roussel Inc PRESS RELEASE 1998 July 01
4. 316338 Drug development pipeline: Napsagatran. Roche Products Ltd COMPANY COMMUNICATION 1999 February 25
5. 324085 Drug development pipeline: Desirudin. Rhone Poulenc Rorer Inc COMPANY COMMUNICATION 1999 May 10
6. 331881 Drug development pipeline: Terbogrel, BIBR-1048 and ion channel blockers. Boehringer Ingelheim GmbH COMPANY COMMUNICATION 1999 July 14
7. 414268 Identification and in vitro characterization of BIBR 953 ZW, a novel synthetic low molecular weight direct thrombin inhibitor. Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HWM, Wienen W THROMB HAEMOST 2001 86 Suppl Abs 755P
8. 414278 Effects of the direct thrombin inhibitor BIBR953ZW and its orally active prodrug BIBR1048MS on experimentally-induced clot formation and template bleeding time in rats. Wienen W, Nar H, Ries UJ, Priepke HWM, Hauel NH, Stassen JM THROMB HAEMOST 2001 86 Suppl Abs 761P
9. 414296 Ex vivo anticoagulant activity of BIBR953ZW, a novel sythethic direct thrombin inhibitor and its prodrug BIBR1048 MS in different animal species. Stassen JM, Hauel NH, Nar H, Ries UJ, Priepke HMW, Wienen W THROMB HAEMOST 2001 86 Suppl Abs 763P
10. 415891 Pharmacokinetics of the synthetic direct thrombin inhibitor BIBR 953 ZW in different animal species. Busch U, Schmid J THROMB HAEMOST 2001 86 Suppl Abs P766
11. 418740 Pharmacodynamics of the synthetic direct thrombin inhibitor BIBR-953ZW in healthy subjects. Stassen JM, Rathgen K, Zimmermann R, Wienen W, Stangier J THROMB HAEMOST 2001 86 Suppl Abs OC160
12. 418741 Antithrombotic effects of the direct thrombin inhibitor BIBR-953ZW and its orally active prodrug BIBR1048MS in a model of venous thrombosis in rabbits. Wienen W, Nar H, Ries UJ, Priepke HWM, Hauel NH, Stassen JM THROMB HAEMOST 2001 86 Suppl Abs OC853
13. 450012 Structure-based design of novel potent nonpeptide thrombin inhibitors. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W J MED CHEM 2002 45 9 1757-1766
14. 485143 Annual Press Conference 2003 Boehringer Ingelheim Corp Company Communication 2003 April 08
15. 498037 Pharmacokinetics of BIBR 953 ZW, the active form of the oral direct thrombin inhibitor BIBR 1048, in patients undergoing hip replacement. Stangier J, Nehmiz G, Liesenfeld KH, Holzschuh L, Hermansson K, Svaerd R, Dahl OE, Ahnfelt L, Eriksson BI J THROMB HAEMOST 2003 1 Suppl 1 Abs P1916
16. 522276 Serine proteases as targets for antithrombotic therapy. Ries UJ, Wienen W DRUGS FUTURE 2003 28 4 355-370
17. 613843 A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. Eriksson BI, Dahl OE, Bueller HR, Hettiarachchi R, Rosencher N, Bravo M-L, Ahnfelt L, Piovella F, Stangier J, Kalebo P, Reilly P J THROMB HAEMOST 2005 3 1 103 • In this phase II trial the highest doses of dabigatran etexilate were associated with a significantly lower incidence of VTE compared with enoxaparin, although the risk of serious bleeding increased dose-dependently with dabigatran etexilate.
18. 620470 Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects. Stangier J, Stähle H, Rathgen K HAEMOSTASIS 2005 3 Suppl 1 Abs 1809
19. 620513 Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran in a dose finding trial in atrial fibrillation. Stangier J, Nehmiz G, Reilly P, Ezekowitz M, Petersen KE, Simmers T, Wallentin L HAEMOSTASIS 2005 3 Suppl 1 Abs 2195
20. 620527 Pharmacokinetics and pharmacodynamics of direct thrombin inhibitor dabigatran in elderly healthy subjects. Stangier J, Stähle H, Rathgen K, Seitz CH HAEMOSTASIS 2005 3 Suppl 1 Abs 2207
21. 640426 A phase I double-blind, ascending dose study of an oral synthetic direct thrombin inhibitor, TGN167. Combe S, Allen G, Kennedy A BLOOD 2005 106 11 Abs 1863
22. 646463 Most extensive thromboembolic disease clinical trial program launched by Boehringer Ingelheim. Boehringer Ingelheim Corp PRESS RELEASE 2006 January 18
23. 650468 AstraZeneca withdraws Exanta due to liver damage risk. AstraZeneca plc PRESS RELEASE 2006 February 14
24. 659999 Daiichi Sankyo Inc company website. Daiichi Sankyo Inc COMPANY WORLD WIDE WEB SITE 2006 April 03
25. 677540 NCT00329238: Secondary prevention of venous thrombo embolism. WWW.CLINICALTRIALS.GOV 2006 May 23
26. 736620 Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: A population model analysis. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J BR J CLIN PHARMACOL 2006 62 5 527-537 • The pharmacokinetic-pharmacodynamic characteristics of dabigatran etexilate in hip replacement patients from the BISTRO I trial are described. ECT provided a more precise description of the anticoagulant effect than aPTT.
27. 734869 Bristol-Myers Squibb Company reports financial results for the third quarter and first nine months of 2006. Bristol-Myers Squibb Co PRESS RELEASE 2006 October 26
28. 746794 Dabigatran inhibits arterial thrombosis in a porcine model of cyclic flow reduction. van Ryn J, Priepke H, Ries UJ, Hauel N, Stassen JM, Wienen W BLOOD 2006 108 11 Abs 906
29. 748377 NCT00262600: Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate. WWW.CLINICALTRIALS.GOV 2006 December 05
30. 748387 NCT00291330: Efficacy and safety of dabigatran compared to warfarin for 6 month treatment of acute symptomatic venous thromboembolism. WWW.CLINICALTRIALS.GOV 2006 February 13
31. 748392 NCT00246025: A study of BIBR 1048 in prevention of venous thromboembolism in patients with TKR surgery. WWW.CLINICALTRIALS.GOV 2006 October 31
32. 750136 Positive phase 3 results for new fixed oral dose anticoagulant presented at 48th Annual Meeting of the American Society of Hematology. Boehringer Ingelheim Pharmaceuticals Inc PRESS RELEASE 2006 December 11
33. 750233 A new oral anticoagulant, dabigatran etexilate, is effective and safe in preventing venous thromboembolism after total knee replacement surgery. Eriksson BI, Dahl OE, van Dijk CN, Frostick SP, Kurth AA, Rosencher N, Schnee J, Hettiarachchi R, Christiansen AV, Hantel S, Buller HR BLOOD 2006 108 11 Abs 573
34. 759358 Current issues in anticoagulation. Agnelli G PATHOPHYSIOL HAEMOST THOMB 2005 34 1 2-9
35. 767281 NCT00133731: The SEPIA-PCI trial: Otamixaban in comparison to heparin in subjects undergoing non-urgent percutaneous coronary intervention. WWW.CLINICALTRIALS.GOV 2006 September 11
36. 771074 NCT00439725: Rivaroxaban in the long term prevention of recurrent symptomatic venous thromboembolism: The Einstein-extension study. WWW.CLINICALTRIALS.GOV 2007 February 28
37. 775707 Annual report & Form 20-F 2006 - AstraZeneca plc. AstraZeneca plc ANNUAL REPORT 2007 March 01
38. 779025 Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Troconiz IE, Tillmann C, Liesenfeld KH, Schafer HG, Stangier J J CLIN PHARMACOL 2007 47 3 371-382 • The differences observed in the pharmacokinetics of dabigatran were reported to be due to alterations in gastric motility and pH following surgery.
39. 779026 Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stahle H, Rathgen K, Svard R J CLIN PHARMACOL 2005 45 5 555-563
40. 796952 Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. Eriksson BI, Dahl OE, Ahnfelt L, Kalebo P, Stangier J, Nehmiz G, Hermansson K, Kohlbrenner V J THROMB HAEMOST 2004 2 9 1573-1580 • In this phase II trial, dabigatran etexilate demonstrated an acceptable safety profile when administrated within the therapeutic range.
41. 803752 Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N J THROMB HAEMOST 2007 5 6 1237-1242
42. 803839 The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W BR J CLIN PHARMACOL 2007 May 15
43. 809710 Pharmacokinetics of BIBR 953 ZW, a novel low molecular weight direct thrombin inhibitor in healthy volunteers. Stangier J, Rathgen K, Gansser D, Kohlbrenner V, Stassen JM THROMB HAEMOST 2001 86 Suppl Abs OC2347
44. 810058 Direct thrombin inhibitors. Nisio MD, Middeldorp S, Büller HR N ENGL J MED 2005 353 10 1028-1040 • This review describes the synthesis, biochemical characterization and effects of direct thrombin inhibitors, including dabigatran etexilate, and includes results from clinical trials regarding the prevention of venous thromboembolism.
45. 810152 Synthetic selective inhibitors of coagulation Factor Xa strongly inhibit thrombin generation without affecting initial thrombin forming time necessary for platelet activation in hemostasis. Ieko M, Tarumi T, Takeda M, Naito S, Nakabayashi T, Koike T J THROMB HAEMOST 2004 2 4 612-618
46. 810153 The hemostatic system. Stassen JM, Arnout J, Deckmyn H CURR MED CHEM 2004 11 17 2245-2260
47. 810158 New anticoagulants. Bauer KA HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM, Washington, DC, USA 2006 450-456
48. 810160 Development of direct thrombin inhibitors in comparison with glycosaminoglycans. Markwardt F SEMIN THROMB HEMOST 2001 27 5 523-530
49. 810162 Hirudin as alternative anticoagulant - a historical review. Markwardt F SEMIN THROMB HEMOST 2002 28 5 405-414
50. 810164 PETRO-investigators. Safety and efficacy of a new oral direct thrombin inhibitor dabigatran in atrial fibrillation: A dose finding trial with comparison to warfarin. Wallentin L, Ezekowitz M, Simmers TA, Pedersen KE, Stangier J, Nehmiz G, Hettiarachchi R, Reilly P EUR HEART J 2005 26 Suppl 482-483
51. 810166 The PETRO-EX investigators. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. CEREBROVASC DIS 2006 21 Suppl 4 Abs 5
52. 810169 Management of venous thromboembolism: Past, present, and future. Hyers TM ARCH INTERN MED 2003 163 7 759-768
53. 810438 In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N THROMB HAEMOST 2007 98 1 155-162
54. 811969 Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Diener HC, Executive Steering Committee on behalf of the SPORTIFF III and V investigators CEREBROVASC DIS 2006 21 4 279-293
55. 811982 Long-term safety and efficacy of dabigatran etexilate: A novel direct thrombin inhibitor in patients with atrial fibrillation. EUROPEAN STROKE CONFERENCE 2006 May 19 Abs 5
56. 812366 Phase 3 results for dabigatran etexilate, an investigational oral anticoagulant, presented today at the XXIst congress of the International Society on Thrombosis and Haemostasis. Boehringer Ingelheim Corp PRESS RELEASE 2007 July 11
57. 812496 Further phase III data shows dabigatran etexilate, a new oral anticoagulant, is effective and safe in preventing venous thromboembolism after orthopaedic surgery. Boehringer Ingelheim Corp PRESS RELEASE 2007 July 11
58. 813184 Heterogeneity of synthetic Factor Xa inhibitors. Gerotziafas GT, Samama MM CURR PHARM DESIGN 2005 11 30 3855-3876
59. 813185 Oral anticoagulants in development: Focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Eriksson BI, Quinlan DJ DRUGS 2006 66 11 1411-1429
60. 815906 Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N THROMB HAEMOST 2007 98: in press
61. 815908 Effect of recombinant Factor VIIa or activated prothrombin complex concentrate on the bleeding time in anaesthetized rats during anticoagulant treatment with the direct thrombin inhibitor dabigatran. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N J THROMB HAEMOST 2005 3 Suppl 1 Abs P1703